Sylvester Comprehensive Cancer Center

E-mail a Friend

Ronan T. Swords, M.D., Ph.D., FRCPI, FRCPath

General Information

Ronan T. Swords, M.D., Ph.D., FRCPI, FRCPath

Languages

  • English

CV

Specialties

  • Hematology/Oncology - Internal Medicine

Roles

  • Assistant Professor of Medicine
  • Co-Chair, Clinical Research Services Advisory Committee
  • Co-Leader, Leukemia/Lymphoma/Myeloma Site Disease Group
  • Member, Epigenetics Working Group
  • Member, Molecular Oncology and Experimental Therapeutics (MOET) Program
  • Member, Phase I Clinical Trials Program

Clinical Interests

In my clinic, I primarily see patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). I am particularly interested in novel drug therapies for these diseases. I am also interested in clinical device trials and our recent studies led to the approval of a new and improved technique for bone marrow aspiration and biopsy  (see below). Patients attending the clinic can expect multidisciplinary care relating to diagnosis and management,  where our goal is to provide a  team approach to conventional care treatment, stem cell transplantation and investigational treatment plans. 

OnControl Device – Swords et al

Awards

Clinical Research Training Institute (CRTI) ASH scholarship award
FECS/AACR/ASCO "Methods in Cancer Biology Workshop" scholarship award
Oppenheimer Outstanding Researcher of the Year Award
FECS/AACR/ASCO joint “Methods in Clinical Cancer Research” scholarship award

Education

2012 PhD, protein homeostasis in AML
National University of Ireland Galway
2011 FRCPI
Royal College of Physicians of Ireland
2009 Advanced Fellowship, Drug Development
University of Texas Health Science Center San Antonio
2007 FRCPath, Fellowship, Hematology
Royal College of Pathologists London, UK
2002 MRCPI, internal medicine internship and residency
Royal College of Physicians of Ireland
2000 MD (Hons)
National University of Ireland Galway


Publications

  • Stein BL, Swords R, Hochhaus A, Giles F. Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia. 2014 Jun 3, Epub ahead of print.
  • Giles FJ, Krawczyk J, O'Dwyer M, Swords R, Freeman C. The role of inflammation in leukaemia. Adv Exp Med Biol. 2014;816:335-60
  • O'Dwyer ME, Swords R, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, Conneally E. Nilotinib 300mg BID as frontline treatment of CML: Prospoective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leuk Res. 2014 Mar;38(3):310-5
  • Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ. Perifosine--a new option in treatment of acute myeloid leukemia? Expert Opin Investig Drugs. 2013 Oct;22(10):1315-27
  • Krawczyk J, Keane N, Freeman CL, Swords R, O’Dwyer M, Files FL. 5-Azacytadine for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2013 April 27.
  • Freeman C, Keane N, Swords R, Giles F. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin Pharmacother. 2013 Jul;14(10):1417-27.
  • Pimentel A, Velez M, Barahona LJ, Swords R, Lekakis L. New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies. Future Oncol. 2013 May;9(5):681-97
  • Keane N, Freeman C, Swords R, Giles FJ. Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Rev Hematol. 2013 Feb;6(1):9-24.
  • Swords R, Santini V. In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? Hematology Am Soc Hematol Educ Program. 2012;2012:74-5.
  • Keane N, Freeman C, Swords R, Giles FJ. EPHA3 as a novel therapeutic target inthe hematological malignancies. Expert Rev Hematol. 2012 Jun;5(3):325-40.
  • Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7.
  • Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 2012 Oct;26(10):2176-85.
  • Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. Eur J Clin Invest. 2012 Sep;42(9):1016-26
  • Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol. 2012 Feb;5(1):81-96.
  • Freeman CL, Swords R, Giles FJ. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? Expert Rev Hematol. 2012 Feb;5(1):17-26.
  • Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.LeukRes.2012 Apr;36(4):e71-3.
  • Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol. 2012 Feb;5(1):81-96.
  • Freeman CL, Swords R, Giles FJ. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? Expert Rev Hematol. 2012 Feb;5(1):17-26.
  • Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.LeukRes.2012 Apr;36(4):e71-3.
  • Miller LJ, Philbeck TE, Montez DF, Puga TA, Brodie KE, Cohen SC, Spadaccini C, Swords R, Brenner AJ. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematol Rep. 2011 Jan 13;3(1):e8.
  • Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. The Pim kinases: new targets for drug development. Curr Drug Targets. 2011 Dec;12(14):2059-66.
  • Swords RT, Dezube BJ, Medeiros BC. Personalized medicine for acute myelogenous leukemia--at the entrance gate. Am J Hematol. 2011 Aug;86(8):631-2.
  • Swords RT, Anguita J, Higgins RA, Yunes AC, Naski M, Padmanabhan S, Kelly KR, Mahalingam D, Philbeck T, Miller L, Puga TA, Giles FJ, Kinney MC, Brenner AJ. A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. J Clin Pathol. 2011 Sep;64(9):809-13.
  • Burke AC, Swords RT, Kelly K, Giles FJ. Current status of agents active against the T315I chronic myeloid leukemia phenotype. Expert Opin Emerg Drugs. 2011 Mar;16(1):85-103.
  • Alvarado Y, Swords R, Kelly KR, Giles FJ. Clinical activity of laromustine (Onrigin™) in hematologic malignancies. Expert Rev Hematol. 2009 Oct;2(5):481-8.
  • Swords RT, Kelly KR, Cohen SC, Miller LJ, Philbeck TE, Hacker SO, Spadaccini CJ, Giles FJ, Brenner AJ. Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently. J Clin Pathol. 2010 Jun;63(6):562-5.
  • Aine Carol Burke, Ronan Swords, Kevin Kelly, Francis Giles. Current status of agents active against the T315I chronic myeloid leukemia phenotype. Expert Opin. Emerging Drugs (2010) 16(1):85-103.
  • 25. Meng Wang, Bruno Madeiros, Harry Erba, Dan DeAngelo, Frank Giles, Ronan Swords. Targeting Protein Neddylation : A Novel Therapeutic Strategy for the Treatment of Cancer. Expert Opinion on Therapeutic Targets 2011 Mar;15(3):253-64.
  • Ting Lu, Ronan Swords, Francis Giles, Kevin Kelly. Nilotinib: A review of its use in drug resistant chronic myeloid leukemia. Clinical Medicine Insights: Therapeutics 2010:2 841-848
  • Kelly K, Swords R, Mahalingam D, Giles FJ. Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents. Leuk Lymphoma. 2010 Aug;51(8):1399-413.
  • Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W,Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson G, Battiwalla M, Giles FJ, LeeKP, Padmanabhan S. Heat shock protein 90 regulates the expression of Wilms' tumor1 protein in myeloid leukemias. Blood. 2010 Jul 22.
  • Swords RT, Kelly KR, Cohen SC, Miller LJ, Philbeck TE, Hacker SO, Spadaccini CJ, Giles FJ, Brenner AJ. Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently. J Clin Pathol. 2010 Jun;63(6):562-5.
  • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9. F1000 Evaluation by Ronan Swords and Francis Giles, July 2010.

Biography

Dr. Swords is very interested in experimental therapeutics and has been involved in several early phase I/II trials testing new compounds for myeloid blood cancers.

Dr. Swords featuring new Chronic Myeloid Leukemia (CML) Drug
Dr. Swords featuring new Acute Myeloid Leukemia (AML) Drug

 



Dr. Swords received his undergraduate medical degree with honors from the National University of Ireland Galway, in 2000. After completing his internship and residency in Ireland he became a member of the Royal College of Physicians of Ireland (MRCPI) in 2002 and a fellow of the college (FRCPI) in 2011. Following a 5 year hematology fellowship, he then went on to graduate as  a fellow of the Royal College of Pathologists, London (FRCPath) in 2007 and the following year, he moved to the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center San Antonio (UTSCSA) to pursue his interests in myeloid malignancies and patient oriented research. There, he completed an advanced fellowship in drug development, followed by a PhD in pharmacology and AML biology, under the mentorship and supervision of Dr. Frank Giles, a world leader in early phase drug development.  His research led to the development of a novel first in class inhibitor of NEDD8 protein conjugation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Following completion of his PhD, Dr. Swords moved to the University of Miami in March of 2012, where he is currently leading the development of the leukemia program under the supervision of Dr. Stephen Nimer.

 

Dr. Swords is a clinical researcher in myeloid blood cancers. In addition to the foundation training outlined, he qualified for a number of scholarship workshops relating to the practical aspects of drug development which included the FECS/AACR/ASCO joint “Methods in Clinical Cancer Research” and “Methods in Cancer Biology Workshop” awards . He also received an ASH mentored research scholarship award  (the Clinical Research Training Institute award),  again in the area of new drug development. Dr. Swords has published over 100 peer reviewed manuscripts and abstracts (see above) in the area of myeloid neoplasia and thematically, his publications focus on translational science and early phase clinical trials for these diseases. Dr. Swords has given oral presentations at local and international meetings including the American Society of Hematology (ASH) and the European Hematology Association (EHA) relating to AML therapeutics. He serves on the editorial board for Leukemia Research Reports and is a manuscript reviewer for a number of high impact factor journals including Blood and Leukemia. He has received funding from private foundations as well as pharma to co

E-mail a Friend